ArticleBritish journal of cancer2009
Annexin II represents metastatic potential in clear-cell renal cell carcinoma.
Article in British journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Overexpression of ANXA2 predicts adverse outcomes of patients with malignant tumors: a systematic review and meta-analysis.Medical oncology (Northwood, London, England) · 2015Pooled it
- Effect of Annexin A2 on prognosis and sensitivity to immune checkpoint plus tyrosine kinase inhibition in metastatic renal cell carcinoma.Discover oncology · 2024Article
- Potential prognostic and therapeutic value of ANXA8 in renal cell carcinoma: based on the comprehensive analysis of annexins family.BMC cancer · 2023Article
- The intricate role of annexin A2 in kidney: a comprehensive review.Renal failure · 2023Review
- Higher Expression of Annexin A2 in Metastatic Bladder Urothelial Carcinoma Promotes Migration and Invasion.Cancers · 2022Article
- Therapeutic Strategies for Disseminated Intravascular Coagulation Associated with Aortic Aneurysm.International journal of molecular sciences · 2022Review
- Annexin A2 and Kidney Diseases.Frontiers in cell and developmental biology · 2022Review
- Knockdown of Annexin A2 Enhances Radiosensitivity by Increasing G2/M-Phase Arrest, Apoptosis and Activating the p38 MAPK-HSP27 Pathway in Nasopharyngeal Carcinoma.Frontiers in oncology · 2022Article
- Management of disseminated intravascular coagulation associated with aortic aneurysm and vascular malformations.International journal of hematology · 2021Review
- Annexin A2 in Inflammation and Host Defense.Cells · 2020Review
- Crucial role of Anxa2 in cancer progression: highlights on its novel regulatory mechanism.Cancer biology & medicine · 2019Article
- The prognostic value of S100A10 expression in cancer.Oncology letters · 2019Review
- MicroRNA-206 regulates the epithelial-mesenchymal transition and inhibits the invasion and metastasis of prostate cancer cells by targeting Annexin A2.Oncology letters · 2018Article
- Identification of natural compounds targeting Annexin A2 with an anti-cancer effect.Protein & cell · 2018Article
- Article
- Role of Annexin A2 in the EGF-induced epithelial-mesenchymal transition in human CaSki cells.Oncology letters · 2017Article
- Article
- Biological characteristics of a novel giant cell tumor cell line derived from spine.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- From plasminogen to plasmin: role of plasminogen receptors in human cancer.International journal of molecular sciences · 2014Review
- Annexin A2: its molecular regulation and cellular expression in cancer development.Disease markers · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnnexin II (ANX2) is a multi-functional protein involved in cell proliferation and membrane physiology and is related to cancer progression. The purpose of this study was to assess ANX2 expression in clear-cell (cc) renal cell carcinoma (RCC).
methodsThe ANX2 expression in 18 primary ccRCCs was examined by real-time reverse transcriptase (RT)-PCR and western blot analyses. Furthermore, immunohistochemical study was performed using paraffin section of 154 primary ccRCCs and 24 metastases. The association between ANX2 expression and the clinicopathological factors and prognosis was analysed.
resultsThe ANX2 was upregulated at both mRNA and protein levels in 14 of 18 primary ccRCCs. Immunohistochemical analysis showed that ANX2 was positive in 73 (47.4%) of 154 primary ccRCC and in 21 (87.5%) of 24 metastatic tumours. The ANX2 expression in the primary tumours showed significant associations with a higher stage, a higher nuclear grade. In patients without metastasis, the 5-year metastasis-free rate in patients with ANX2-positive tumour was significantly lower than that in those with ANX2-negative tumour (63.0% vs 90.1%; P<0.0001). Multivariate analysis showed that ANX2 expression is an independent predictor for metastasis.
conclusionOur findings suggest that ANX2 expression might be a novel predictor of the metastatic potential of ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.